Source: GrowBLOX Sciences Inc, Press Release, June 3 2014
GrowBLOX Sciences, Inc. Announces Puerto Rico Subsidiary
LAS VEGAS, June 3, 2014 /PRNewswire/ — GrowBLOX Sciences, Inc. (OTCQB: GBLX) a biotechnology and research company, announced today it has formed its subsidiary, GB Sciences Puerto Rico, Inc. The Company recognizes Puerto Rico’s geographic location as a premier distribution and exporting outlet for medical-grade marijuana products. The Company has been monitoring Puerto Rico’s pending legislation to legalize medical marijuana. GrowBLOX Sciences considers Puerto Rico to be a preeminent outlet to accomplish its objective by utilizing The Company’s patent-pending proprietary indoor growing technology for commercial cultivation of medical-grade products.
Puerto Rico is currently debating decriminalizing marijuana, legalizing medical marijuana, and allowing the territory to grow all at once. Rather than taking the slow road to reform that many states seem to be content with, pro-marijuana Puerto Ricans are aiming to pass legislations quickly. This is where The Company sees opportunity and has positioned themselves accordingly to take advantage of the pending legislation. The Drug Policy Alliance and their influential Executive Director, Dr. Ethan Nadelmann, recently challenged Puerto Rican lawmakers by stating, “Puerto Rico’s drug related crime statistics are staggering. If we want to change that, we need to create a movement for marijuana reform, and I hope to see a movement when I come back.”
Puerto Rico’s governor, Alejandro Garcia Padilla, recently took to the airways on a popular local radio show acknowledging the undeniable fact that cannabis has a very real medicinal value. He was quoted, “There seems to be a consensus around the notion that marijuana can be used to successfully treat many illnesses, such as multiple sclerosis, glaucoma, and cancer.”
Since opening the subsidiary, Craig Ellins, CEO of GrowBLOX Sciences, has appointed Jose A. Axtmayer as a member to the Board of Directors and President of GB Sciences Puerto Rico, Inc. “I am thrilled to bring Jose A. Axtmayer on board for our Puerto Rico subsidiary. Jose brings with him a wealth of knowledge and experience in various financial enterprises and is the ideal partner to navigate through the legislative process. By joining GB Sciences Puerto Rico, he aids in the strengthening of our infrastructure and gives invaluable insight into the Puerto Rico market,” said Ellins. Axtmayer is a graduate of Yale University, Yale Graduate School and Yale Law School. He has been privately practicing law in New York and Puerto Rico for over 30 years, during which he has held principal roles in numerous financial and infrastructure projects in Puerto Rico.
Puerto Rico possess the facilities and human resource capabilities for GrowBLOX Sciences and is an ideal setting for both, the research and manufacturing of medical-grade products. It is The Company’s intention to work in conjunction with local municipalities in devising standardization for the cultivation, extraction, testing and distribution of medical-grade products from nutraceuticals to pharmaceuticals through its proprietary technology.
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation. The GrowBLOX chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions. http://www.gbsciences.com
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CEO, GrowBLOX Sciences, Inc.
+1-844-843-BLOX ext. 01
SOURCE GrowBLOX Sciences, Inc.